Drug Design of GLP-1 Receptor Agonists: Importance of In Silico Methods

Author(s): Smriti Sharma, Vinayak Bhatia*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 8 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Drug design based on degradation-resistant, long-acting Glucagon-like peptide-1 receptor (GLP-1R) agonists for treating type 2 diabetes is attracting a lot of attention. Here, the authors have examined in detail how in silico drug design is aiding in developing novel GLP-1 receptor agonist drugs. Their pharmacotherapy and adverse effects have also been summarized. After the analysis of currently available information on this topic, the authors feel that in silico method is a great auxiliary tool in almost all the experimental studies on GLP-1 receptors and is highly efficient in identifying novel drug molecules that can act as GLP-1 receptor agonists.

Keywords: GLP-1, Type 2 diabetes mellitus (T2DM), GLP-1 receptor agonists, In Silico, CADDD, molecular docking, drug design.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 8
Year: 2021
Published on: 08 April, 2021
Page: [1015 - 1024]
Pages: 10
DOI: 10.2174/1381612826666201118094502
Price: $65

Article Metrics

PDF: 127